Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.81 |
| ▸ | LMNA | P02545 | 3/20 | 0.81 |
| ▸ | TP53 | P04637 | 3/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.81 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2',4'-Dihydroxychalcone SCHEMBL1411695 | 1.00 | MAPT (1.00) | MAPTCYP3A4MEN1KMT2AHPGD | |
| 2',4'-Dihydroxychalcone SCHEMBL25200440 | 1.00 | MAPT (1.00) | MAPTCYP3A4MEN1KMT2AHPGD | |
| Isoliquiritigenin SCHEMBL9448612 | 0.93 | CYP3A4 (0.86) | MAPTCYP3A4MEN1KMT2AHPGD | |
| Isoliquiritigenin SCHEMBL9448617 | 0.93 | CYP3A4 (0.86) | MAPTCYP3A4MEN1KMT2AHPGD | |
| SCHEMBL25208375 | 0.91 | MEN1 (0.96) | MAPTCYP3A4MEN1KMT2AHPGD | |
| Isoliquiritigenin SCHEMBL1519061 | 0.91 | CYP3A4 (0.83) | MAPTCYP3A4MEN1KMT2AHPGD | |
| SCHEMBL25194934 | 0.91 | CYP3A4 (0.83) | MAPTCYP3A4MEN1KMT2AHPGD | |
| SCHEMBL25195193 | 0.90 | MEN1 (0.82) | MAPTCYP3A4MEN1KMT2AHPGD | |
| SCHEMBL28093997 | 0.90 | MEN1 (0.82) | MAPTCYP3A4MEN1KMT2AHPGD | |
| Isoliquiritigenin SCHEMBL10408923 | 0.90 | CYP3A4 (1.00) | MAPTCYP3A4MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260096569-A1 | EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES | APEEL TECH INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260060940-A1 | NUCLEOTIDE-BINDING DOMAIN AND LEUCINE-RICH REPEAT PROTEIN 3 INFLAMMASOME INHIBITOR FOR TREATING INFLAMMATORY INTESTINAL DISEASES | UNIV MACAU (CN) | 2026-03-05 | — | — | US | claimed |
| EP-4496476-A1 | GAS PHASE TREATMENT OF PRODUCE | Apeel Technology, Inc. (US) | 2025-01-29 | — | — | EP | claimed |
| US-20240373850-A1 | Compositions comprising resinous exudate metabolites from plants of the genus Adesmia, used to control and treat infections in plant crops; and methods for controlling infections in plant crops. | PONTIFICIA UNIV CATOLICA DE VALPARAISO (CL) | 2024-11-14 | — | — | US | claimed |
| CN-117320559-A | Edible coating with antimicrobial properties | 阿比尔技术公司 | 2023-12-29 | — | — | CN | claimed |
| WO-2023183341-A1 | GAS PHASE TREATMENT OF PRODUCE | APEEL TECHNOLOGY, INC. (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| WO-2022221968-A1 | COMPOSITIONS COMPRISING RESINOUS EXUDATE METABOLITES FROM PLANTS OF THE GENUS ADESMIA, USED TO CONTROL AND TREAT INFECTIONS IN PLANT CROPS; AND METHODS FOR CONTROLLING INFECTIONS IN PLANT CROPS | PONTIFICIA UNIVERSIDAD CATÓLICA DE VALPARAÍSO (CL) | 2022-10-27 | — | — | WO | claimed |
| US-20220330565-A1 | EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES | APEEL TECHNOLOGY, INC. | 2022-10-20 | — | — | US | claimed |
| US-10314811-B2 | Compositions and methods for selectively inhibiting intestinal carboxylesterase 2 enzyme activity | THE METHODIST HOSPITAL (US) | 2019-06-11 | — | — | US | claimed |
| US-20180235928-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY INHIBITING INTESTINAL CARBOXYLESTERASE 2 ENZYME ACTIVITY | METHODIST HOSPITAL (US) | 2018-08-23 | — | — | US | claimed |
| EP-3337563-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY INHIBITING INTESTINAL CARBOXYLESTERASE 2 ENZYME ACTIVITY | The Methodist Hospital (US) | 2018-06-27 | — | — | EP | claimed |
| WO-2017034919-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY INHIBITING INTESTINAL CARBOXYLESTERASE 2 ENZYME ACTIVITY | THE METHODIST HOSPITAL (US) | 2017-03-02 | — | — | WO | claimed |
| EP-0800387-B1 | CHALCONES AND ESTERS THEREOF WITH ANTIPROLIFERATIVE ACTIVITY IN UTERUS, OVARY AND BREAST TUMOURS | INDENA SPA (IT) | 2002-08-28 | — | — | EP | claimed |
| US-5808137-A | Chalcones and esters thereof with antiproliferative activity in uterus, ovary and breast tumors | INDENA S.P.A. (IT) | 1998-09-15 | — | — | US | claimed |
| EP-0800387-A1 | CHALCONES AND ESTERS THEREOF WITH ANTIPROLIFERATIVE ACTIVITY IN UTERUS, OVARY AND BREAST TUMOURS | INDENA S.p.A. (IT) | 1997-10-15 | — | — | EP | claimed |
| WO-1996019209-A1 | CHALCONES AND ESTERS THEREOF WITH ANTIPROLIFERATIVE ACTIVITY IN UTERUS, OVARY AND BREAST TUMOURS | INDENA S.P.A. (IT) | 1996-06-27 | — | — | WO | claimed |
| US-20260096569-A1 | EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES | APEEL TECH INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-0502205-A1 | CHALCONE DERIVATIVE AND ULTRAVIOLET SCREENING COSMETIC | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 1992-09-09 | — | — | EP | disclosed |
| US-4111907-A | PHOTOPOLYMERIZABLE KETONES | CIBA-GEIGY CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060940-A1 | NUCLEOTIDE-BINDING DOMAIN AND LEUCINE-RICH REPEAT PROTEIN 3 INFLAMMASOME INHIBITOR FOR TREATING INFLAMMATORY INTESTINAL DISEASES | NLRP3, NLRP1, NOD1 | MAPT 926/4885CYP3A4 914/4885MEN1 4828/4885 |
| US-20240373850-A1 | Compositions comprising resinous exudate metabolites from plants of the genus Adesmia, used to control and treat infections in plant crops; and methods for controlling infections in plant crops. | ERG28, RXFP4, CROCC | MAPT 4500/4885CYP3A4 1006/4885MEN1 2124/4885 |
| US-20260096569-A1 | EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES | CYP51A1, ERG28, NISCH | MAPT 4702/4885CYP3A4 3888/4885MEN1 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.